RVPH News and Press, Reviva Pharmaceuticals Holdings Inc. From 10/31/23

2023-10-31 08:17:59 ET Mersana Therapeutics  ( MRSN ) +21% Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056. Pinterest ( PINS ) +16% soars as Wall Street is impressed with turnaround strategy. Wolfspeed  ( WOLF ) +13%...

2023-10-30 13:43:38 ET Gainers: Miromatrix Medical MIRO +216% . Eargo ( EAR ) +52% . Kaixin Auto Holdings ( KXIN ) +49% . Reviva Pharmaceuticals Holdings ( RVPH ) +45% . Conduit Pharmaceuticals ( CDT ) +40% . Primech Holdings Ltd...

2023-10-30 10:26:23 ET More on Reviva Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER Seeking Alpha’s Quant Rating on Reviva Pharmaceuticals Historical earnings data for Reviva Pharmaceuticals Financial information for Reviv...

- Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale (PANSS) total score vs. placebo at week 4, p<0.001 - - Statistically significant and clinically meanin...

ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV,...

2023-09-27 02:48:56 ET Summary Reviva Pharmaceuticals is running a phase 3 study of brilaroxazine in schizophrenia called RECOVER, with results expected in October 2023. A previous phase 2 study showed that brilaroxazine had significant antipsychotic activity, and a potentially di...

CUPERTINO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous sys...

ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m...

CUPERTINO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous sys...

- 402 patients completed enrollment across multiple sites in the US, Europe, and Asia – - Topline data for Phase 3 RECOVER study expected in October 2023 - - Completion of 1-year open-label extension clinical study expected in Q3 2024 - CUPERTINO, Calif., Aug. 17, 2...